These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 2139975)

  • 1. [Current aspects of tissue renin-angiotensin systems: atrial natriuretic peptide and prostaglandins in arterial hypertension].
    Ferreira Montero IJ
    Rev Esp Cardiol; 1990; 43 Suppl 1():24-33. PubMed ID: 2139975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic prospects of renin-angiotensin system inhibition.
    Corvol P
    Clin Exp Hypertens A; 1989; 11 Suppl 2():463-70. PubMed ID: 2691125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the renin-angiotensin system by atrial natriuretic peptide.
    Johnston CI; Phillips PA; Arnolda L; Mooser V
    J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S43-6. PubMed ID: 1708022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure.
    Packer M
    Circulation; 1988 Jun; 77(6 Pt 2):I64-73. PubMed ID: 2967129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the renin-angiotensin system in vascular health: use of ACE inhibition to improve vascular function.
    Izzo JL
    Heart Dis; 2000; 2(5):380-3. PubMed ID: 11728286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrelation of coronary effects of atrial natriuretic peptide and the renin-angiotensin system in the isolated perfused rat heart.
    Bauer WR; Neubauer S; Obitz G; Ertl G
    J Mol Cell Cardiol; 1994 Apr; 26(4):527-37. PubMed ID: 8072008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
    [No Abstract]   [Full Text] [Related]  

  • 8. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renaissance of the renin-angiotensin system in the pathogenesis and therapy of arterial hypertension].
    Horký K
    Cas Lek Cesk; 1989 Sep; 128(37):1161-5. PubMed ID: 2805032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Humoral mechanisms in the pathogenesis of arterial hypertension with emphasis on the renin-angiotensin-aldosterone system and natriuretic substances].
    Horký K
    Vnitr Lek; 1989 Mar; 35(3):219-25. PubMed ID: 2525299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The renin-angiotensin system and its inhibition (author's transl)].
    Corvol P; Elkik F; Thibonnier M; Plouin PF; Menard J
    Nouv Presse Med; 1981 Apr; 10(19):1525-30. PubMed ID: 6269554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered regulation of renal interstitial hydrostatic pressure and the renal renin-angiotensin system in the absence of atrial natriuretic peptide.
    O'Tierney PF; Komolova M; Tse MY; Adams MA; Pang SC
    J Hypertens; 2008 Feb; 26(2):303-11. PubMed ID: 18192845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?
    Sambhi MP; Gavras H; Robertson JI; Smith WM
    West J Med; 1993 Mar; 158(3):286-94. PubMed ID: 8460511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the renin--angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function.
    Neutel JM
    J Hum Hypertens; 2004 Sep; 18(9):599-606. PubMed ID: 15190263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Clin Sci (Lond); 2008 May; 114(10):635-42. PubMed ID: 18052934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polypeptides and antagonists].
    Regoli D
    Sem Hop; 1984 Mar; 60(14):987-1002. PubMed ID: 6202006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide.
    Semplicini A; Ceolotto G; Sartori M; Maresca A; Baritono E; De Toni R; Paparella I; Calò L
    J Nephrol; 2002; 15(5):489-96. PubMed ID: 12455714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial natriuretic hormone: a regulator of blood pressure and volume homeostasis.
    Laragh JH; Atlas SA
    Kidney Int Suppl; 1988 Sep; 25():S64-71. PubMed ID: 2972865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sympathetic and renin-angiotensin systems contribute to increased blood pressure in sucrose-fed rats.
    Freitas RR; Lopes KL; Carillo BA; Bergamaschi CT; Carmona AK; Casarini DE; Furukawa L; Heimann JC; Campos RR; Dolnikoff MS
    Am J Hypertens; 2007 Jun; 20(6):692-8. PubMed ID: 17531930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.